Inotek Pharmaceuticals Corporation announced today that it has closed a Series C financing, raising $19.3 million. All of Inotek’s previous investors participated in the round, including Pitango Venture Capital, Care Capital LLC, La Caisse de dépôt et placement du Québec, MedImmune Ventures, and Rho Ventures. Inotek added three additional investors in the Series C round: Hercules Technology Growth Capital, Inc., Meditor Capital Management, and Mitsubishi UFJ Capital.

“With several of our programs nearing clinical proof of concept, this round of financing provides us with the resources to generate first proof of efficacy data for at least three separate internal therapeutic programs. It will also fund the expansion of our development team to support our long-term growth,” said Andrew Salzman, M.D., Inotek’s President & CEO. “I am pleased by the continued support shown by our existing investors and look forward to working with our newest partners, Meditor, Mitsubishi UFJ Capital, and Hercules.”